Skip to main content
Journal of Patient-Reported Outcomes
Fig. 3 | Journal of Patient-Reported Outcomes

Fig. 3

From: Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group

Fig. 3

Mean score improvement from randomization to 8 months follow-up for the six domains with statistically significant and clinically meaningful improvement at 8 months follow-up

Blue* indicates time points with statistically significant and clinically meaningful improvement for the observation group. Red* indicates time points with statistically significant and clinically meaningful improvement for the carfilzomib-dexamethasone (Kd) maintenance group

Back to article page